-
平臺編號：bio-68857
-
國際編號：CRL-1631?
-
細胞信息： Y3-Ag 1.2.3
-
規(guī)格：frozen
-
用途：ATCC原裝細胞
-
服務費用：
加載中…… - 訂購
-
注意事項：僅用于科學研究或者工業(yè)應用等非醫(yī)療目的不可用于人類或動物的臨床診斷或治療，非藥用，非食用（產品信息以出庫為準）
Y3-Ag 1.2.3
品系：Lou
ATCC Number：CRL-1631?
相關疾病：多發(fā)性骨髓瘤
數(shù)量：大量
細胞類型：B淋巴細胞
是否是腫瘤細胞：0
物種來源：大鼠
生長狀態(tài)：懸浮生長
運輸方式：凍存運輸
細胞形態(tài)：淋巴樣
免疫類型：kappa light chain
規(guī)格：0.5ml Designations: Y3-Ag 1.2.3
Depositors: ?K Yamada
Isotype: kappa light chain
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension
Organism: Rattus norvegicus deposited as Rattus sp.
Morphology:lymphoblast
Source: Disease: plasmacytoma; myeloma
Strain: Lou
Cell Type: B lymphoblast;
Cellular Products:immunoglobulin
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Restrictions:the depositor has provided these cells for research purposes only and with the following restrictions: (1) no distribution should be made to third parties, (2) any proposed commercial use must be negotiated with the National Research Development Corporation, 101 Newington Causeway, London SE1 6BU, (3) all papers reporting any use of these or derived clones should make direct reference to the original publication (Nature 277:131-133, 1979)
Comments:This is a derivative of the S210 myeloma developed by C. Milstein.
No commercial use or third party distribution is permitted without the concurrence of C. Milstein.
The cells are resistant to 8-azaguanine, are HAT sensitive and can be used as a fusion partner for rat B cells to make rat - rat hybridomas.
Tested and found negative for ectromelia virus (mousepox).
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Subculturing: Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 to 2 X 10 exp5 viable cells/ml.
Maintain cell density between 1 X 10 exp5 and 1 X 10 exp6 viable cells/ml.
Preservation: culture medium 95%; DMSO, 5%
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2002
recommended serum:ATCC 30-2020
References: 1090: Galfre G, et al. Rat x rat hybrid myelomas and a monoclonal anti-Fd portion of mouse IgG. Nature 277: 131-133, 1979. PubMed: 310519
26115: Bazin H, et al. Transplantable immunoglobulin-secreting tumours in rats. I. General features of LOU-Ws1 strain rat immunocytomas and their monoclonal proteins. Int. J. Cancer 10: 568-580, 1972. PubMed: 4668496
ATCC Number：CRL-1631?
相關疾病：多發(fā)性骨髓瘤
數(shù)量：大量
細胞類型：B淋巴細胞
是否是腫瘤細胞：0
物種來源：大鼠
生長狀態(tài)：懸浮生長
運輸方式：凍存運輸
細胞形態(tài)：淋巴樣
免疫類型：kappa light chain
規(guī)格：0.5ml Designations: Y3-Ag 1.2.3
Depositors: ?K Yamada
Isotype: kappa light chain
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension
Organism: Rattus norvegicus deposited as Rattus sp.
Morphology:lymphoblast
Source: Disease: plasmacytoma; myeloma
Strain: Lou
Cell Type: B lymphoblast;
Cellular Products:immunoglobulin
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Restrictions:the depositor has provided these cells for research purposes only and with the following restrictions: (1) no distribution should be made to third parties, (2) any proposed commercial use must be negotiated with the National Research Development Corporation, 101 Newington Causeway, London SE1 6BU, (3) all papers reporting any use of these or derived clones should make direct reference to the original publication (Nature 277:131-133, 1979)
Comments:This is a derivative of the S210 myeloma developed by C. Milstein.
No commercial use or third party distribution is permitted without the concurrence of C. Milstein.
The cells are resistant to 8-azaguanine, are HAT sensitive and can be used as a fusion partner for rat B cells to make rat - rat hybridomas.
Tested and found negative for ectromelia virus (mousepox).
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Subculturing: Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 to 2 X 10 exp5 viable cells/ml.
Maintain cell density between 1 X 10 exp5 and 1 X 10 exp6 viable cells/ml.
Preservation: culture medium 95%; DMSO, 5%
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2002
recommended serum:ATCC 30-2020
References: 1090: Galfre G, et al. Rat x rat hybrid myelomas and a monoclonal anti-Fd portion of mouse IgG. Nature 277: 131-133, 1979. PubMed: 310519
26115: Bazin H, et al. Transplantable immunoglobulin-secreting tumours in rats. I. General features of LOU-Ws1 strain rat immunocytomas and their monoclonal proteins. Int. J. Cancer 10: 568-580, 1972. PubMed: 4668496
